Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018223112) PREDICTING GASTRIC CANCER TREATMENT OUTCOME
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/223112 International Application No.: PCT/US2018/035788
Publication Date: 06.12.2018 International Filing Date: 04.06.2018
IPC:
A61K 45/00 (2006.01) ,A61P 35/00 (2006.01) ,C07K 14/47 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
46
from vertebrates
47
from mammals
Applicants:
EXPRESSION PATHOLOGY, INC. [US/US]; 9600 Medical Center Drive, Suite 300 Rockville, MD 20850, US
Inventors:
HEMBROUGH, Todd; US
CECCHI, Fabiola; US
SCHWARTZ, Sarit; US
YAU, Christina; US
Agent:
BOOTH, Paul, M.; US
ALDAG, Andrew, J.; US
DEBOY, Mark; US
EDELL, Ira, C.; US
CROSLAND, David, W.; US
Priority Data:
62/514,36402.06.2017US
Title (EN) PREDICTING GASTRIC CANCER TREATMENT OUTCOME
(FR) PRÉDICTION DES RÉSULTATS D'UN TRAITEMENT DU CANCER DE L'ESTOMAC
Abstract:
(EN) Methods are provided for identifying whether a cancer patient, and especially a gastric cancer patient, will be responsive to treatment with a sequential therapeutic strategy comprising a first administration of the FOLFIRI regimen (irinotecan/5-fluoruracil/folinic acid) followed by a separate sequential administration of the combination of the chemotherapy agents docetaxel and cisplatin (FOLFIRI + docetaxel/cisplatin). Specified TUBB3 and TYMP fragment peptides are precisely detected and quantitated by SRM-mass spectrometry directly in tumor cells, and especially gastric cancer tumor cells, that are collected from tumor tissue obtained from a cancer patient and compared to reference levels in order to determine if the cancer patients will positively respond to treatment with the sequential combination treatment of FOLFIRI + docetaxel/cisplatin.
(FR) L'invention concerne des méthodes visant à identifier si un patient atteint de cancer, et en particulier un patient atteint d'un cancer de l'estomac, répondra à un traitement consistant en une stratégie thérapeutique séquentielle comprenant une première administration du protocole FOLFIRI (irinotécan/5-fluoruracile/acide folinique) suivie d'une administration séquentielle séparée de l'association des agents chimiothérapeutiques docétaxel et cisplatine (FOLFIRI + docétaxel/cisplatine). Les fragments peptidiques TUBB3 et TYMP spécifiés sont détectés et quantifiés avec précision par spectrométrie de masse en mode SRM directement dans des cellules tumorales, et en particulier des cellules tumorales du cancer de l'estomac, qui sont collectées à partir de tissu tumoral provenant d'un patient atteint de cancer, et les mesures sont comparées à des niveaux de référence afin de déterminer si les patients atteints de cancer répondront positivement à un traitement par le traitement d'association séquentiel FOLFIRI + docétaxel/cisplatine.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)